Erratum to Research Resource: Nuclear Receptors as Transcriptome: Discriminant and Prognostic Value in Breast Cancer (Molecular Endocrinology, (2013), 27, (350-365)doi:10.1210/me.2012-1265);Research resource: Nuclear receptors as transcriptome: Discriminant and prognostic value in breast cancer

Molecular Endocrinology

Volumn 27, Issue 2, 2013, Pages 350-365

  Muscat, George E O ^a   Eriksson, Natalie A ^a   Byth, Karen ^b   Loi, Sherene ^d   Graham, Dinny ^c   Jindal, Shalini ^e   Davis, Melissa J ^f   Clyne, Colin ^g,i   Funder, John W ^g   Simpson, Evan R ^g   Ragan, Mark A ^a   Kuczek, Elizabeth ^b   Fuller, Peter J ^g   Tilley, Wayne D ^e   Leedman, Peter J ^h   Clarke, Christine L ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d JULES BORDET INSTITUTE   (Belgium)

^e University of Adelaide   (Australia)

^f Queensland Facility for Advanced Bioinformatics   (Australia)

^g HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; COUP TFII PROTEIN; EAR2 PROTEIN; ER ALPHA PROTEIN; LRH1 PROTEIN; MESSENGER RNA; NUCLEAR RECEPTOR NUR77; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; RAR GAMMA PROTEIN; TAMOXIFEN; TR ALPHA PROTEIN; TR BETA PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL;

EID: 84873024915     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1250     Document Type: Erratum

References (40)

1. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF 2010 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141
2. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L 2012 Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16-32
3. Conzen SD 2008 Nuclear receptors and breast cancer. Mol Endocrinol 22:2215-2228
4. Riggins RB, Mazzotta MM, Maniya OZ, Clarke R 2010 Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocr Relat Cancer 17:R213-R231
5. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ 2006 Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126:789-799
6. Holbeck S, Chang J, Best AM, Bookout AL, Mangelsdorf DJ, Martinez ED 2010 Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. Mol Endocrinol 24:1287-1296
7. Wang SC, Myers SA, Eriksson NA, Fitzsimmons RL, Muscat GE 2011 Nr4a1 siRNA expression attenuates α-MSH regulated gene expression in 3T3-L1 adipocytes. Mol Endocrinol 25:291-306
8. Glover T, Mitchell K 2008 An introduction to biostatistics. 2nd ed. Long Grove, IL: Waveland Press
9. Crowther LM, Wang SC, Eriksson NA, Myers SA, Murray LA, Muscat GE 2011 Chicken ovalbumin upstream promoter-transcription factor II regulates nuclear receptor, myogenic, and metabolic gene expression in skeletal muscle cells. Physiol Genomics 43:213-227
10. Goni R, Garcia P, Foissac S 2009 The qPCR data statistical analysis. Integromics White Paper
11. Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer Jr CE, Wickerham DL, Wolmark N, Paik S 2011 Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor positive breast cancer. J Clin Oncol 29:4160-4167
12. Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo AM, Jeong W, Mills GB, Safe S, Lee JS 2012 Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med 4:52-67
13. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C 2007 Definition of clinically distinct molecular subtypes in estrogen receptorpositive breast carcinomas through genomic grade. J Clin Oncol 25:1239-1246
14. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C 2008 Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9:239
15. Zhao Y, Bruemmer D 2010 NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol 30:1535-1541
16. Volakakis N, Kadkhodaei B, Joodmardi E, Wallis K, Panman L, Silvaggi J, Spiegelman BM, Perlmann T 2010 NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc Natl Acad Sci USA 107:12317-12322
17. Lee SO, Abdelrahim M, Yoon K, Chintharlapalli S, Papineni S, Kim K, Wang H, Safe S 2010 Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Res 70:6824-6836
18. Mohan HM, Aherne CM, Rogers AC, Baird AW, Winter DC, Murphy EP 2012 Molecular pathways: the role of NR4A orphan nuclear receptors in cancer. Clin Cancer Res 18:3223-3228
19. Alexopoulou AN, Leao M, Caballero OL, Da Silva L, Reid L, Lakhani SR, Simpson AJ, Marshall JF, Neville AM, Jat PS 2010 Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res 12:R51
20. Lennard L 1992 The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43:329-339
21. Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G 1995 Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346:796-798
22. Yang C, Yu B, Zhou D, Chen S 2002 Regulation of aromatase promoter activity in human breast tissue by nuclear receptors. Oncogene 21:2854-2863
23. Nagasaki S, Suzuki T, Miki Y, Akahira J, Shibata H, Ishida T, Ohuchi N, Sasano H 2009 Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression. Cancer Sci 100:639-645
24. Miki Y, Clyne CD, Suzuki T, Moriya T, Shibuya R, Nakamura Y, Ishida T, Yabuki N, Kitada K, Hayashi S, Sasano H 2006 Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of insitu steroidogenesis. Cancer Lett 244:24-33
25. Chand AL, Herridge KA, Thompson EW, Clyne CD 2010 The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion. Endocr Relat Cancer 17:965-975
26. Clyne CD, Speed CJ, Zhou J, Simpson ER 2002 Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J Biol Chem 277:20591-20597
27. Thiruchelvam PT, Lai CF, Hua H, Thomas RS, Hurtado A, Hudson W, Bayly AR, Kyle FJ, Periyasamy M, Photiou A, Spivey AC, Ortlund EA, Whitby RJ, Carroll JS, Coombes RC, Buluwela L, Ali S 2011 The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat 127:385-396
28. Annicotte JS, Chavey C, Servant N, Teyssier J, Bardin A, Licznar A, Badia E, Pujol P, Vignon F, Maudelonde T, Lazennec G, Cavailles V, Fajas L 2005 The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. Oncogene 24:8167-8175
29. Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW, Dairkee SH 2002 Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res 62:1939-1943
30. Ling Y, Xu X, Hao J, Ling X, Du X, Liu X, Zhao X 2010 Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients. Cancer Genet Cytogenet 196:140-145
31. Ryan J, Curran CE, Hennessy E, Newell J, Morris JC, Kerin MJ, Dwyer RM 2011 The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One 6:e16023
32. Silva JM, Domínguez G, González-Sancho JM, García JM, Silva J, García-Andrade C, Navarro A, Muñoz A, Bonilla F 2002 Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21:4307-4316
33. Guigon CJ, Kim DW, Willingham MC, Cheng SY 2011 Mutation of thyroid hormone receptor-beta in mice predisposes to the development of mammary tumors. Oncogene 30:3381-3390
34. Zhu XG, Park KS, Kaneshige M, Bhat MK, Zhu Q, Mariash CN, McPhie P, Cheng SY 2000 The orphan nuclear receptor Ear-2 is a negative coregulator for thyroid hormone nuclear receptor function. Mol Cell Biol 20:2604-2618
35. Papadaki I, Mylona E, Giannopoulou I, Markaki S, Keramopoulos A, Nakopoulou L 2005 PPARγ expression in breast cancer: clinical value and correlation with ERβ. Histopathology 46:37-42
36. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP 2003 Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 79:391-397
37. Fenner MH, Elstner E 2005 Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer. Expert Opin Investig Drugs 14:557-568
38. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y 2004 Can PPARγ ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 4:465-477
39. + breast cancer. Ann Oncol 23:1771-1780
40. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP 2006 GenePattern 2.0. Nat Genet 38:500-501